Stocks and InvestingStocks and Investing
Mon, June 12, 2023
Fri, June 9, 2023
Thu, June 8, 2023
Wed, June 7, 2023

Andreas Argyrides Reiterated (ASND) at Buy and Held Target at $187 on, Jun 7th, 2023


Published on 2024-10-28 04:15:13 - WOPRAI, Andreas Argyrides
  Print publication without navigation


Andreas Argyrides of Wedbush, Reiterated "Ascendis Pharma A/S" (ASND) at Buy and Held Target at $187 on, Jun 7th, 2023.

Andreas has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 3 agree with Andreas's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tiago Fauth of "Credit Suisse" Maintained at Hold with Increased Target to $89 on, Friday, April 28th, 2023
  • Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $109 on, Friday, April 28th, 2023
  • Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, April 5th, 2023


These are the ratings of the 3 analyists that currently disagree with Andreas


  • Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $152 on, Thursday, June 1st, 2023
  • David Lebowitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $146 on, Wednesday, April 5th, 2023
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $92 on, Tuesday, April 4th, 2023